Dr. Wan Fariza Binti Wan Jamaludin adalah seorang dokter spesialis Hematologi Klinis dan Penyakit Dalam yang berpraktik di beberapa institusi medis terkemuka di Malaysia, termasuk Prince Court Medical Centre
Bachelor of Medicine and Bachelor of Surgery (MBBS), St. George's Hospital Medical School, University of London, England.
Member of the Royal College of Physicians, United Kingdom (MRCP UK)
Member of the Academy of Medicine (Malaysia)
Fellowship of the Royal College of Physicians, United Kingdom (FRCP UK)
Fellowship of Clinical Haematology (MSH)
Specialist Registrar Haematology, Royal Devon & Exeter Hospital, England (NHS UK) 2007-2008.
Specialist Registrar Haematology, Musgrove Park Hospital, Somerset, England (NHS UK) 2009.
Senior Lecturer Haematology, Universiti Teknologi MARA Selayang, Malaysia 2010-2012.
Deputy Head, Cell Therapy Centre, (Bone Marrow Transplantation), Pusat Perubatan Universiti Kebangsaan Malaysia, 2018-2020.
Associate Professor, Consultant Physician and Clinical Haematologist, Pusat Perubatan Universiti Kebangsaan Malaysia, 2012-2022.
Adjunct Professor, Taylor's University School of Medicine, Malaysia 2023.
Malaysian Society of Haematology (Member)
Malaysian Society of Transplantation (Member)
University award Q1 Research Publication: Dengue infection associated hemophagocytic syndrome: Therapeutic interventions and outcome (2015).
National award Best Oral & Poster Presentation: The Value of 18-FDG PETCT Scan Versus Bone Marrow Biopsy in Detecting and Predicting the Outcomes of Patient with Bone Marrow Involvement in 18F-FDG Avid Lymphoma (2017).
Good Citizen Award for volunteering health programs in PPR Bukit Jalil - Persatuan Zhong Yuan Puchong Selatan (2017).
University award for research grant: The Value of PET/CT scan in Determining Remission Status in Lymphoma Patients Involving the Head & Neck Region (2019).
University award for external research grant with Monash University: The Asia Pacific Myeloma and Related Diseases Registry (2020).
National award Best Oral & Poster Presentation: Clinical Outcomes of Relapsed or Refractory Diffuse Large B Cell Lymphoma - A Multicenter Real-World Study in Malaysia (2022)
